Last reviewed · How we verify

NCT04763213: non-STEMI

New Predictors in Determining the Need for Invasive Treatment in Non-STEMI

Completed Last updated 21 February 2021
What this trial tests

trial testing Coronary Angiography in Myocard Infarctus in 276 participants. Completed in 31 December 2019.

Timeline
1 January 2018
Primary endpoint
31 December 2019
31 December 2019

Quick facts

Lead sponsorKahramanmaras Sutcu Imam University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment276
Start date1 January 2018
Primary completion31 December 2019
Estimated completion31 December 2019
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kahramanmaras Sutcu Imam University

Who can join

18 and older, any sex, with Myocard Infarctus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Non-ST elevation acute coronary syndrome (NSTE-ACS) is a heterogeneous disease with a wide range of treatment options from the medical follow-up to early invasive treatment due to complete occlusion of the culprit artery. Non-ST elevation myocardial infarction acute coronary syndrome (NSTEMI-ACS) is one of the subcomponents of NSTE-ACS, which has an increased mortality rate, and for which early intervention can be vital. Yet, most of these patients require invasive treatment. In fact, some of them are patients who require very early invasive treatment and have a complete occlusion in the culprit artery. Unfortunately, risk scoring systems are not sufficient enough to differentiate these patients. Therefore, the discovery of markers that can be used in the differentiation of NSTEMI-ACS patients with an increased need for invasive treatment and/or complete occlusion of the culprit's vessels, especially during pandemic periods such as the COVID-19 pandemic, has gained importance. Inflammation is known to play an important role in the etiopathogenesis of coronary artery disease. To the best of our knowledge, there is a lack of literature on the relationship between the need for invasive treatment strategy and/or complete occlusion of the culprit's vessel, and the hematological markers in patients diagnosed with NSTEMI-ACS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Coronary Angiography

Trials testing the same drug.

Other Kahramanmaras Sutcu Imam University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04763213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing